Nyrada, Inc. · ASX:NYR
Nyrada — ShareCafe Hidden Gems Webinar (September 2022)
18 slides from Nyrada's conference presentation, Sep 29, 2022
Slide 1: Presentation to ShareCafe Hidden Gems Webinar
29th September 2022 Sydney, Australia Presentation to ShareCafe Hidden Gems Webinar Nyrada Inc (ASX: NYR) is pleased to provide investors with the attached presentation, which will be given by Nyrada CEO, James Bonnar at the ShareCafe Hidden Gems Webinar, from 12.30pm AEST on 30th September 2022. Th
Slide 2: Forward-Looking Statements
Media Enquiries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com Forward-Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”
Slide 3: Slide 3
Slide 4: Slide 4
Slide 5: Slide 5
Slide 6: Slide 6
Slide 7: Cholesterol-Lowering Drug Program
Cholesterol-Lowering Drug Program Novel small molecule PCSK9 Inhibitor
Slide 8: Cholesterol-Lowering Market
Cholesterol-Lowering Market Population, Problem, Opportunity 56 million 18.4 million between ages 40 and 75 Unable to achieve treatment eligible LDL-C target despite taking a statin1 62.6 million 27.4 million 1 in 5 patients Americans have high cholesterol1 statin intolerant3 taking a statin1 Global
Slide 9: Current PCSK9 Injectable Drugs
Current PCSK9 Injectable Drugs Expensive and Inconvenient Effective when combined with statin treatment Expensive US$5,800 to US$6,500 per year Inconvenient for patient / poor compliance Expensive to manufacture Insurer / patient co-pay reluctance (US) • Patient convenience: once per day oral treatm
Slide 10: Benchmarking Efficacy
Benchmarking Efficacy NYX-PCSK9i +/- Lipitor® in Transgenic Mouse Hyperlipidemia Model Study Objective: Results: Determine if additive reduction in total cholesterol can be • NYX-PCSK9i + Lipitor® achieves 65% total achieved with combination statin therapy cholesterol reduction • APOE*3Leiden.CETP m
Slide 11: Efficacy in Model of Atherosclerosis
Efficacy in Model of Atherosclerosis NYX-PCSK9i in Human Tissue-Engineered Blood Vessel Model6 Study Design Results: • Researchers at Duke University (US) used human stem cells • Optimised analog of NYX-PCSK9i reduced cell to create tissue-engineered blood vessels (TEBVs), adhesion (blocking athero
Slide 12: Program Milestones and Path to the Clinic
Program Milestones and Path to the Clinic 2H CY2020 1H CY2021 2H CY2021 UPCOMING JUL 2021 DEC 2021 CY2022 - CY2023 DEC 2020 MAY 2021 USPTO Charles River Preclinical studies to commence NYX-PCSK9i shows Potent new drug grants patent for Laboratories in H2 CY2022 57% reduction in total candidates Nyra
Slide 13: Phase I Study Design
Phase I Study Design OBJECTIVES • Evaluate safety, tolerability, and pharmacokinetics of optimised analog of NYX-PCSK9i • Measure changes in LDL-cholesterol in healthy volunteers and exploratory patient population cohorts PARTICIPANTS • 10 cohorts (6 active: 2 placebo per cohort) DESIGN • Double-bli
Slide 14: Corporate Snapshot
Corporate Snapshot ASX:NYR NYRADA INC (ASX:NYR) 12 CORPORATE PRESENTATION
Slide 15: Corporate Snapshot
Corporate Snapshot Key Metrics Market capitalisation A$20.3M (as at 28 September 2022) Share price A$0.13 (as at 28 September 2022) CDIs free float 156,008,700 Cash at bank 30 June 2022: A$10.8M • Adequate funding for Phase I studies ASX listing January 16, 2020 NYRADA INC (ASX:NYR) 13 CORPORATE PRE
Slide 16: Management Team with Proven Industry Experience
Management Team with Proven Industry Experience High calibre Board with proven track record in realising the value of biotech companies: • John Moore Chairman • Christopher Cox Non-Executive Director James Bonnar - CEO Cameron Jones - CFO Dr Benny Evison - CSO • Marcus Frampton • Business executive
Slide 17: References
References 1 Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016 2 Brain Injury Alliance (Connecticut): http://www.biact.org/understanding-brai
Slide 18: ASX:NYR
Brain Injury Solution Cholesterol-Lowering Animation Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 16 CORPORATE PRESENTATION
Nyrada — ShareCafe Hidden Gems Webinar (September 2022) on 6ix